In sepsis-induced lung injury, the ferroptosis-related SLC7A11/GSH/GPX4 signaling pathway is downregulated. Ferrostatin-1 activates this pathway and protects the lungs.
Our findings demonstrate that DEAF1 attenuates ADR-induced apoptosis and pyroptosis in MM by enhancing DNA damage repair and suppressing GSDME cleavage via the FER/GSDME axis. This study provides a novel therapeutic target for the treatment of MM.
Our data demonstrate that AP can induce ferroptosis in colorectal cancer by downregulating the SLC7A11/GPX4 signaling pathway, with P53 potentially serving as its target.
4 months ago
Journal
|
GPX4 (Glutathione Peroxidase 4) • FER (FER Tyrosine Kinase) • SLC7A11 (Solute Carrier Family 7 Member 11)
Inhibition of DPP9 improves sorafenib sensitivity by promoting ferroptosis in HCC, which provides novel evidence for DPP9 as an HCC treatment target synergizing with sorafenib.
6 months ago
Journal
|
FER (FER Tyrosine Kinase) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
In summary, FER could serve as a prognostic indicator and therapeutic target in DLBCL. Additionally, the application of exosomes in diagnosis or treatment may open up novel avenues for cancer therapy.
7 months ago
Journal
|
FER (FER Tyrosine Kinase) • AJUBA (Ajuba LIM Protein)
Additionally, after PCJNF treatment, we observed significant alterations in the expression of migration-and invasion-related proteins, such as vimentin and E-cadherin. In conclusion, these findings suggest that TRIP13 may serve as a potential therapeutic target for EMs and that PCJNF offers a promising new approach for integrating Traditional Chinese Medicine with modern medical treatments.
8 months ago
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • VIM (Vimentin) • FER (FER Tyrosine Kinase) • TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) • TRIP13 (Thyroid Hormone Receptor Interactor 13)
We report the first two cases of soft tissue tumors harboring ACTB::FER fusions and expand the molecular spectrum of mesenchymal tumors with kinase gene alterations. Further, we highlight the importance of target-agnostic approaches for the detection of rare kinase fusions, which may not be included on targeted next-generation sequencing panels.
Serum levels of CA125, CA15-3, and CA19-9 could act as associated markers for SLE-ILD. Serum SCC, CYFRA21-1 and FER levels may also be linked to kidney involvement in SLE-ILD.
Expression quantitative trait loci analysis indicated that the FER rs7716388 G allele was associated with the up-regulation of FER mRNA expression levels in lung tissue. Our results indicated that these two functional SNPs in the FRGs may be prognostic biomarkers for the prognosis of NSCLC patients, and the possible mechanism may be through modulating the expression of their corresponding genes.
To our knowledge, the SH3PXD2B::FER fusion has never been reported previously. Whether the current case represents an example of a plexiform myofibroblastic tumor or a distinct tumor entity remains to be determined.
Taken together, our findings not only provide insights into the essential role of FER as a tumor suppressor in tumor initiation and progression but also highlight its potential as a target for future clinical diagnosis.